|
PF-30996 |
LAMICTAL 50 mg comprimidos dispersables/masticables |
2013-07-21 |
|
Glaxo Wellcome Foundation Limited |
Reino Unido
|
Glaxosmithkline Guatemala S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-59258 |
AUGMENTIN BID 200-28.5 mg/5mL Polvo para suspensión oral |
2026-04-07 |
|
Laboratoire GlaxoSmithKline |
Francia
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-59850 |
AUGMENTIN BID 400-57mg/5mL Polvo para suspensión oral |
2026-08-13 |
|
Glaxosmithkline |
Francia
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-35475 |
RELENZA 5 mg Polvo para inhalación |
2025-02-18 |
|
Glaxosmithkline |
Francia
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-39462 |
FASTURTEC 1.5 mg/mL polvo y solucion para uso parenteral |
2012-09-04 |
|
Sanofi Aventis |
Francia
|
Agefinsa (Agencia Farm. Intern., S.A.) |
Lanquetin S.A. |
Sanofi-Aventis de Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-43008 |
AUGMENTIN ES 600-42.9 mg/5mL Polvo para suspensión oral |
2028-08-22 |
|
GlaxoSmithkline Produtos Farmacéuticos, Lda. |
Francia
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-49594 |
AUGMENTIN SR 1000-62.5 mg Tabletas recubiertas de acción sostenida |
2024-01-29 |
|
Glaxosmithkline, S.A. |
Francia
|
Glaxosmithkline Guatemala |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-18922 |
ADENOCOR 6 mg/2 mL solucion inyectable |
2007-09-29 |
|
Sanofi-synthelabo France |
Francia
|
Centro Distribuidor S.A. |
Colon S.A. |
Agencias J.i. Cohen |
Lanquetin S.A. |
Resco S.A. |
Solymer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-25205 |
RELENZA 5 mg Polvo para inhalación |
2005-05-19 |
|
Glaxo Wellcome Production |
Francia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-26166 |
DENIBAN 400 mg Comprimidos recubiertos ranurados |
2011-06-27 |
|
Sanofi Aventis |
Francia
|
Agencias J. I. Cohen |
Americana S.A. |
Centro Distribuidor S.A. |
Colon S.A. |
Lanquetin S.A. |
Sanofi-Aventis de Guatemala, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|